Brokerages Anticipate Aratana Therapeutics Inc (PETX) to Post -$0.10 Earnings Per Share

Share on StockTwits

Wall Street analysts expect Aratana Therapeutics Inc (NASDAQ:PETX) to post earnings per share of ($0.10) for the current quarter, according to Zacks. Three analysts have issued estimates for Aratana Therapeutics’ earnings, with estimates ranging from ($0.11) to ($0.09). Aratana Therapeutics reported earnings per share of ($0.19) during the same quarter last year, which would indicate a positive year over year growth rate of 47.4%. The business is scheduled to issue its next earnings report on Thursday, May 2nd.

According to Zacks, analysts expect that Aratana Therapeutics will report full year earnings of ($0.32) per share for the current year, with EPS estimates ranging from ($0.39) to ($0.29). For the next fiscal year, analysts expect that the company will post earnings of $0.12 per share, with EPS estimates ranging from ($0.06) to $0.31. Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Aratana Therapeutics.

Aratana Therapeutics (NASDAQ:PETX) last issued its quarterly earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.06). Aratana Therapeutics had a negative net margin of 41.57% and a negative return on equity of 14.78%. The firm had revenue of $4.91 million for the quarter, compared to the consensus estimate of $6.53 million.

A number of equities research analysts have weighed in on the company. Zacks Investment Research downgraded Aratana Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, March 14th. William Blair downgraded Aratana Therapeutics from an “outperform” rating to a “market perform” rating and set a $4.14 price objective on the stock. in a report on Thursday, January 24th. TheStreet downgraded Aratana Therapeutics from a “c-” rating to a “d+” rating in a report on Monday, March 4th. BidaskClub downgraded Aratana Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, January 11th. Finally, Stifel Nicolaus downgraded Aratana Therapeutics from a “buy” rating to a “hold” rating and decreased their price objective for the company from $8.00 to $5.00 in a report on Friday, January 11th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $6.41.

Shares of PETX opened at $3.83 on Friday. Aratana Therapeutics has a 12-month low of $3.30 and a 12-month high of $7.16. The stock has a market cap of $197.37 million, a P/E ratio of -11.97 and a beta of 1.38.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raymond James & Associates acquired a new position in shares of Aratana Therapeutics in the 4th quarter worth approximately $65,000. Campbell & CO Investment Adviser LLC acquired a new position in shares of Aratana Therapeutics in the 4th quarter worth approximately $88,000. Metropolitan Life Insurance Co. NY boosted its holdings in shares of Aratana Therapeutics by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 17,040 shares of the biopharmaceutical company’s stock worth $104,000 after acquiring an additional 13,308 shares in the last quarter. Creative Planning acquired a new position in shares of Aratana Therapeutics in the 4th quarter worth approximately $127,000. Finally, Hollencrest Capital Management acquired a new position in shares of Aratana Therapeutics in the 4th quarter worth approximately $153,000. 68.63% of the stock is currently owned by institutional investors.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Featured Article: What are the FAANG Stocks?

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Telcoin Price Tops $0.0006 on Major Exchanges
Telcoin Price Tops $0.0006 on Major Exchanges
Crystal Clear  Market Capitalization Tops $26,650.00
Crystal Clear Market Capitalization Tops $26,650.00
SwissBorg  Market Cap Tops $5.04 Million
SwissBorg Market Cap Tops $5.04 Million
OAX Price Hits $0.23 on Major Exchanges
OAX Price Hits $0.23 on Major Exchanges
Haven Protocol Price Tops $0.44 on Top Exchanges
Haven Protocol Price Tops $0.44 on Top Exchanges
SUQA  24 Hour Volume Hits $17,144.00
SUQA 24 Hour Volume Hits $17,144.00


© 2006-2019 Ticker Report